
In this paper, a stochastic Alzheimer's disease model with the effect of calcium on amyloid beta is proposed. The Lyapunov function is constructed, followed by the feasibility and positivity and the existence of a stationary distribution for the positive solutions of the proposed model. The sufficient conditions for the extinction of the stochastic Alzheimer's disease model are derived through the Lyapunov function. This indicates that beta-amyloid plaque and the complex of beta-amyloid oligomers with prion protein may go extinct and there is a possibility of a cure for the disease. Furthermore, our numerical simulations show that as the intensity of the random disturbance increases, the time it takes for the disease to go extinct decreases.
Citation: Ruoyun Lang, Yuanshun Tan, Yu Mu. Stationary distribution and extinction of a stochastic Alzheimer's disease model[J]. AIMS Mathematics, 2023, 8(10): 23313-23335. doi: 10.3934/math.20231185
[1] | Xiaodong Wang, Kai Wang, Zhidong Teng . Global dynamics and density function in a class of stochastic SVI epidemic models with Lévy jumps and nonlinear incidence. AIMS Mathematics, 2023, 8(2): 2829-2855. doi: 10.3934/math.2023148 |
[2] | Yue Wu, Shenglong Chen, Ge Zhang, Zhiming Li . Dynamic analysis of a stochastic vector-borne model with direct transmission and media coverage. AIMS Mathematics, 2024, 9(4): 9128-9151. doi: 10.3934/math.2024444 |
[3] | Jinji Du, Chuangliang Qin, Yuanxian Hui . Optimal control and analysis of a stochastic SEIR epidemic model with nonlinear incidence and treatment. AIMS Mathematics, 2024, 9(12): 33532-33550. doi: 10.3934/math.20241600 |
[4] | Tingting Wang, Shulin Sun . Dynamics of a stochastic epidemic model with quarantine and non-monotone incidence. AIMS Mathematics, 2023, 8(6): 13241-13256. doi: 10.3934/math.2023669 |
[5] | Ying He, Bo Bi . Conditions for extinction and ergodicity of a stochastic Mycobacterium tuberculosis model with Markov switching. AIMS Mathematics, 2024, 9(11): 30686-30709. doi: 10.3934/math.20241482 |
[6] | Xiangming Zhao, Jianping Shi . Dynamic behavior of a stochastic SIR model with nonlinear incidence and recovery rates. AIMS Mathematics, 2023, 8(10): 25037-25059. doi: 10.3934/math.20231278 |
[7] | Yuhuai Zhang, Xinsheng Ma, Anwarud Din . Stationary distribution and extinction of a stochastic SEIQ epidemic model with a general incidence function and temporary immunity. AIMS Mathematics, 2021, 6(11): 12359-12378. doi: 10.3934/math.2021715 |
[8] | Yue Dong, Xinzhu Meng . Stochastic dynamic analysis of a chemostat model of intestinal microbes with migratory effect. AIMS Mathematics, 2023, 8(3): 6356-6374. doi: 10.3934/math.2023321 |
[9] | Ruyue Hu, Chi Han, Yifan Wu, Xiaohui Ai . Analysis of a stochastic Leslie-Gower three-species food chain system with Holling-II functional response and Ornstein-Uhlenbeck process. AIMS Mathematics, 2024, 9(7): 18910-18928. doi: 10.3934/math.2024920 |
[10] | Yan Ren, Yan Cheng, Yuzhen Chai, Ping Guo . Dynamics and density function of a HTLV-1 model with latent infection and Ornstein-Uhlenbeck process. AIMS Mathematics, 2024, 9(12): 36444-36469. doi: 10.3934/math.20241728 |
In this paper, a stochastic Alzheimer's disease model with the effect of calcium on amyloid beta is proposed. The Lyapunov function is constructed, followed by the feasibility and positivity and the existence of a stationary distribution for the positive solutions of the proposed model. The sufficient conditions for the extinction of the stochastic Alzheimer's disease model are derived through the Lyapunov function. This indicates that beta-amyloid plaque and the complex of beta-amyloid oligomers with prion protein may go extinct and there is a possibility of a cure for the disease. Furthermore, our numerical simulations show that as the intensity of the random disturbance increases, the time it takes for the disease to go extinct decreases.
Alzheimer's disease (AD), a major form of dementia, is accompanied by cognitive decline, memory impairment, impaired ability to learn new information and language dysfunction. As one of the top 10 causes of death worldwide today, it will severely affect the daily life of the patient [1]. According to the global burden of disease study in 2019 (GBD 2019), the number of people with Alzheimer's-like dementia has 50 million in 2018 and it will reach 152 million by 2050 [2]. In the USA, total payments for medicare, long-term care, and hospice services for dementia are estimated to be up to fanxiexian_myfh335 billion in 2021 [3]. With no reliable and effective treatment, dementia will affect the patient's ability to perform daily live by impairing cognitive function and pose an increasing challenge to health care systems worldwide [4,5,6].
In the earliest phase of Alzheimer's disease (cellular phase), amoid beta (Aβ) accumulate in the brain, along with the spread of tau pathology [7]. The peptide Aβ, obtained by amyloid precursor protein (APP), can form Aβ oligomers (two main Aβ forms, Aβ40 and Aβ42), which will reduce the number of synapses and decrease glucose metabolism in the brain. This process will finally lead to brain atrophy [8]. To discuss how Aβ peptide aggregates into Aβ oligomers, Masoud Hoore et al. [9] developed a model of Aβ fibrillation on a minimal scale. The results showed that Aβ monomers rapidly increased once Aβ oligomers produced. Furthermore, by considered Aβ40 and Aβ42 as two forms of Aβ oligomers, Li and Zhao [10] proved that the targeted therapeutic drug Aducanumab of Aβ cannot completely cure AD. However, many studies have found that the prion protein (PrPC) inhibits the activity of the protease that cleaves APP and slows the proliferation of Aβ [11,12]. To understand the dynamics of PrPC, Helal et al. [13] devised an in vitro model to study the role of protein and analyzed the kinetics of Aβ plaques, Aβ oligomers, PrPC and Aβ−x−PrPC complex. Considering the process of diffusion of these substances, Hu et al. [14] focused on the dynamic behaviors of the system in a finite time interval and under what conditions the state value may exceed a certain value.
Various factors are involved in the transmission of neural signals. For example, in the cerebrospinal fluid, the level of Aβ oligomers is affected by Ca2+, microglia activity, reactive oxygen species and Na+ concentration etc. [15,16,17,18]. For example, Caluwé and Dupont [19] designed a positive loop between Aβ and Ca2+ to explore the role of Ca2+ on Aβ oligomers during the progression of a healthy pathological state to a severe pathology. All the factors always fluctuate in a small range over long periods which will affect the level of Aβ oligomers and the pathological status of AD. Therefore, stochastic perturbations cannot be ignored and parameters are often assumed in biomathematics to be perturbed by linear functions of white noise, a phenomenon described by stochastic differential equations (SDE) [20,21,22,23]. Hu et al. [24] formulated a stochastic model of the in vivo progression of AD incorporating the role of prions derived from Helal et al. [13] and discussed the existence of the ergodic stationary distribution of the model.
Studies have been done on minimizing the concentrations of Aβ plaques and Aβ−x−PrPC complex in Alzheimer's disease models, but the conditions are complex and not well measured in many practical situations [14]. And the random factors in the interstitial fluid (ISF) cannot be neglected, therefore it is necessary to study stochastic models of Alzheimer's disease to explore the convergence to extinction in a probabilistic sense. For this purpose, we introduce calcium ions into the system based on Helal et al. [12] and consider the effect of random noise on Brownian motion in the environment. The main contributions of this paper are as follows:
(ⅰ) A stochastic Alzheimer's disease model is formulated by taking the influence of calcium ions and environmental noise on Aβ oligomers into account.
(ⅱ) The sufficient conditions for extinction of the model are established.
The remaining paper is organized as follows. In the next section, the mathematical model of Alzheimer's disease with Ca2+ is established. Section 3 shows the existence, uniqueness and boundedness of the solution of the model. The conditions for the existence of a steady state distribution are derived in Section 4. Section 5 focuses on the threshold conditions for the extinction of plaques and complex and shows how random noise affects the development of Alzheimer's disease. In Section 6, a numerical simulation is performed to prove the validity of the theoretical derivation. In the ending section, we present our conclusion.
In this section, we introduce the model and then give the necessary definitions and lemmas.
To explore the role of prions in memory impairment, Helal et al. [13] introduced a mathematical model of in vivo Alzheimer's disease progression that explains the relationship between Aβ plaque, Aβ oligomers, PrPC and Aβ−x−PrPC complex. The model is as follows
{˙A=αun−ηA,˙u=λ2−τup+σb−αnun−ρuA−k2u,˙p=λ3−τup+σb−k3p,˙b=τup−σb−k4b. | (2.1) |
Where A(t),u(t),p(t) and b(t) represent the concentration of Aβ plaque, Aβ oligomers, PrPC and Aβ−x−PrPC complex. Where α is the rate of formation of oligomers, η is the rate of degradation of a plaque, τ is the rate of binding of Aβ oligomers to PrPC, σ is the rate of unbinding of Aβ−x−PrPC, ρ is the conversion rate of oligomers to plaque, ki(i=2,3,4) is the degradation of Aβ oligomers, PrPC and Aβ−x−PrPC complex, λi(i=2,3) is the source of PrPC and Aβ oligomers.
In this paper, by considering that the presence of PrPC can optimize and control Ca2+ input [11] and this process is affected by the level of Ca2+, it can be assumed to be a bilinear model [25,26]. Furthermore, there is positive feedback between the level of Ca2+ and the level of Aβ [19], so Ca2+ is introduced into the model. Moreover, due to the randomness of real life, especially in the neurobiological environment, there exist various random factors involved in signaling. In many stochastic models of infectious diseases, factors such as noise, Brownian motion, pollution, etc. have been considered [27,28,29]. Then, we assume that the white noise in the environment is proportional to the variables C(t), u(t), p(t), b(t), and A(t). The stochastic differential model can be written as
{dC=(λ1+v2u−v3pC−k1C)dt+ξ1CdB1(t),du=(λ2−τup+σb+v1Ck+C−αnun−ρuA−k2u)dt+ξ2udB2(t),dp=(λ3−τup+σb−k3p)dt+ξ3pdB3(t),db=(τup−σb−k4b)dt+ξ4bdB4(t),dA=(αun−ηA)dt+ξ5AdB5(t). | (2.2) |
Where λ1 is the source of Ca2+, v2 is the acceleration of Ca2+ due to Aβ, v3 is the limitation of Ca2+ due to PrPC, k1 is the degradation of Ca2+, v1is the maximal rate of the positive feedback of Ca2+ on Aβ and k is half-saturation constant, Bi(t) denote independent and standard Brownian motions and ξ2i are the intensities of the white noise, i=1,2,3,4,5. The other parameters in model (2.2) have identical significance as in model (2.1). Our main purpose is to explore the threshold related to epidemic transmission and try to establish the threshold dynamics of model (2.2).
Throughout this paper, we let (Ω,F,{F}l⩾0,P) be a complete probability space with filtration {F}l⩾0 satisfying the usual conditions (that is to say, it is increasing and right continuous while F0 contains all P -null sets). Let Bi(t)(i=1,2,3...) denote the independent standard Brownian motions defined on this probability space. We also denote Rd+={x∈Rd:xi>0 for all 1⩽i⩽d} and a∧b=min{a,b}.
Generally speaking, consider the d-dimensional stochastic differential equation (SDE)
dx(t)=f(x(t),t)dt+g(x(t),t)dBt, | (2.3) |
where f(t,x(t)) is a function in Rd defined in [t0,∞]×Rd and g(x(t),t) is a d×m matrix, f, g are locally Lipschitz functions in x. Bt denotes an m-dimensional standard Brownian motion (Bt=(B1(t),B2(t),...,Bm(t))T, Bi(t)(i=1,2,...,m) is standard normal distribution and Bi(t)∼N(0,t)) defined on the complete probability space (Ω,F,{F}t≥0,P). Denote by C2,1(Rd×[t0,∞];R+) the family of all nonnegative functions V(x(t),t) defined on Rd×[t0,∞] such that they are continuously twice differentiable in x and once in t.
We define the differential operator L of Eq (2.3) by [30]
L=∂∂t+d∑i=1fi(x,t)∂∂xi+12d∑i,j=1[gT(x,t)g(x,t)]ij∂2∂xi∂xj. | (2.4) |
If L acts on a function V∈C2,1(Rd×[t0,∞],R+) then
LV(x,t)=Vt(x,t)+Vx(x,t)f(x,t)+12trace[gT(x,t)Vxx(x,t)g(x,t)] | (2.5) |
where Vt(x,t)=∂V∂t, Vx(x,t)=(∂V∂xi,…,∂V∂xd),Vxx(x,t)=(∂2V∂xi∂xj)d×d. From Itô's formula, if x(t)∈Rd, then
dV(x,t)=LV(x,t)dt+Vx(x,t)g(x,t)dBt. | (2.6) |
Here are some definitions and lemmas what we will use in the following text.
Definition 1. [21] (Fokker-Plank equation) The respective Fokker-Plank equation for an unknown probability density function (PDF) in variables x(t) can be assigned to Eq (2.3):
∂∂tp(t,x)=−∂∂x(fp(t,x))+∂2∂x2(12g2p(t,x)), |
where p(t,x) means the probability density function of x(t) at t.
Definition 2. [30] For a set Ωk composed of elementary random events ω, the indicator function of Ωk, denoted by 1Ωk, is the random variable, where
1Ωk={1ifω∈Ωk,0ifω∉Ωk. |
Definition 3. [31] The SDE (2.3) is said to be stochastically ultimately bounded if for any ε∈(0,1), there is a positive constant χ=χ(ε) such that for any initial data {x(t):−τ⩽t⩽0}∈C([−τ,0];Rd+), the solution x(t) of Eq (2.3) has the property that
lim supt→∞P{|x(t)|>χ}<ε. | (2.7) |
Definition 4. [30] For the Markov process {X(t),t⩾0}, the state space is S={1,2,...,T}, if there exists a positive integer m such that
pij(m)>0foreveryi,j∈S, |
then X(t) has the ergodic feature.
Definition 5. [23,24,27] The diffusion matrix of system (2.3) is defined as follows:
A(x)=(ai,j(x)),ai,j(x)=k∑r=1gir(x).gjr(x). |
Definition 6. [23] Let N(t)=(Ni(t))T(i=1,2,...,d) be the solution of model (2.2) with initial value N(0)∈Rd+. If for any 0<ε<1, there exists a pair of positive constants θ=θ(ε) and χ=χ(ε) such that
limt→∞infP{Ni(t)⩾θ}⩾1−ε,limt→∞infP{Ni(t)⩽χ}⩾1−ε |
then the species i is said to be stochastically permanent.
Definition 7. [20,22,28] For model (2.3), the infected individuals xi(t) are said to be extinctive if limt→∞xi(t)=0, almost surely (a.s.).
Lemma 1. [23] (Chebychev inequality) Let X={Xt}t⩾0 be a nonnegative random variable, its mean value is noted as E(X), for a given r>0. Then,
P(X⩾r)⩽1rE(X)foreveryr>0. |
Lemma 2. [21,28] The Markov process X(t) has a unique ergodic stationary distribution μ(⋅) if there exists a bound D⊂Rd with regular boundary Γ and the following conditions:
(1) In the domain D and some neighborhood thereof, the smallest eigenvalue of the diffusion matrix A(x) is bounded away from zero.
(2) There exists a nonnegative C2-function V such that LV is negative for any Rd∖D. Then,
Px{limT→+∞1T∫T0f(X(t))dt=∫Edf(x)μ(dx)}=1 |
for all x∈Rd, where f is a function integrable with respect to the measure μ.
Lemma 3. [20] (Strong Law of Large Number) Let M={M}t⩽0 be continuous and real-valued local martingale, which vanishes as t→0, then
limt→∞⟨M,M⟩t=∞,a.s.,⇒limt→∞Mt⟨M,M⟩t=0,a.s.limt→∞sup⟨M,M⟩tt<0,a.s.,⇒limt→∞Mtt=0,a.s. |
Theorem 1. For any initial value
X(0)=(C(0),u(0),p(0),b(0),A(0))∈R5+, |
there exists a positive salutation X(t)=(C(t),u(t),p(t),b(t),A(t)) of the stochastic model (2.2) for t⩾0 and the solution will hold in R5+ with probability one.
Proof. We can easily know that the coefficients of model (2.2) are locally Lipschitz continuous. Then, for any given initial value (C(0),u(0),p(0),b(0),A(0))∈R5+, there exists a unique local solution (C(0),u(0),p(0),b(0),A(0)) on t∈[0,τe), where τe is the explosion time (see [20]). To prove that the solution is global, all you have to do is to prove τe=∞ almost surely. Let k0⩾0 be sufficiently large so that (C(0),u(0),p(0),b(0),A(0)) all lie within the interval [1k0,k0]. For each integer k⩾k0, define the following stopping time:
τk=inf{t∈[0,τe):min{(C(0),u(0),p(0),b(0),A(0))}⩽1k or max{(C(0),u(0),p(0),b(0),A(0))⩾k}}. |
Where throughout this paper, we setinf∅=∞ (as usual ∅ denotes the empty set). According to the definition of the stopping time, τk is increasing as k→∞. Set τ∞=limt→∞τk with τ∞⩽τe almost surely. Namely, we need to show that τ∞=∞ almost surely. If τ∞≠∞, we assumed that there exists a pair of constants T>0 and ϵ∈(0,1) such that
P{τ∞⩽T}>ϵ. | (3.1) |
As a result, there is an integer k1⩾k0 such that
P{τk⩽T}>ϵ, for all k⩾k1. |
Now, we define a C5-function V(C,u,p,b,A)∈R5+ as follows
V(C,u,p,b,A)=m1(A−1−lnA)+C−1−lnC+m2u−1−lnu+m3P−1−lnP+m4(b−1−lnb), |
where mi(i=1,2,3,4) are positive constants to be determined below. Then, by using the Itô's formula, we have
dV=LVdt+m1(A−1)ξ5dB5(t)+(C−1)ξ1dB1(t)+(m2u−1)ξ2dB2(t)+(m3p−1)ξ3dB3(t)+m4(b−1)ξ4dB4(t), |
where
LV=m1(1−1A)(αun−ηA)+m1ξ252+(1−1C)(λ1+v2u+v3pC−k1C)+ξ212+(m2−1U)(λ2−τup+σb+v1Ck+C−αnun−ρuA−k2u)+ξ222+(m3−1p)(λ3−τup+σb−k3p)+ξ232+m4(1−1b)(τup−σb−k4b)+m4ξ242=m1αun−m1ηA+m1η−m1Aαun+m1ξ252+λ1+v2u+v3pC−k1C+k1−v3p−1C(λ1+v2u)+ξ212+m2λ2−m2(τup−σb)+m2v1Ck+C−m2αnun−m2ρuA−m2k2u+τp+αnun−1+ρA+k2−1u(λ2+σb+v1Ck+C)+ξ222+m3λ3−m3(τup−σb)−m3k3p+τu+k3−1p(λ3+σb)+ξ232+m4(τup−σb)−m4k4b+m4(σ+k4)−m4b⋅τup+m4ξ242⩽−(m2n−m1)αun+αnun−1+(v2−m2k2+τ)u−(m1η−ρ)A+(τ−m3k3)p+m1η+m3ξ252+λ1+k1+ξ212+m2λ2+m2v1+k2+ξ222+m3λ3+k3+ξ232+m4(σ+k4)+m4ξ242+(m4−m2−m3)(τup−σb). |
Choosing
m1=ρη,m2=max{v2+τk2+1,m1n+1}, |
m3=τk3+1,m4=m3+m2, |
such that
v2−m2k2+τ<0,m2n−m1>0,τ−m3k3<0. |
And there exists a constant K such that LV⩽K, where K is define as follows
K:=max{−(m2n−m1)αun+αnun−1+m1η+m3ξ252+λ1+k1+ξ212+m2λ2+m2v1+k2+ξ222+m3λ3+k3+ξ232+m4(σ+k4)+m4ξ242}. |
Integration of the above inequality from 0 to τk∧T and taking the expectation on both sides, we get the following inequality
E(V(C(τk∧T),u(τk∧T),p(τk∧T),b(τk∧T),A(τk∧T)))⩽V(C(0),u(0),p(0),b(0),A(0))+TK. | (3.2) |
Now, we set Ωk={τk⩽T}, k⩾k1. It follows from the inequality (3.1) that P(Ωk)⩾ε. Note that for each ω∈Ωk, C(τk,ω), u(τk,ω), p(τk,ω), b(τk,ω), A(τk,ω) equals either k or 1k. Consequently,
V(V(C(τk∧T),u(τk∧T),p(τk∧T),b(τk∧T),A(τk∧T)))⩾min{k−1−lnk,1k−1+lnk}. | (3.3) |
From (3.2) and (3.3) we get
V(C(0),u(0),p(0),b(0),A(0))+TK⩾E(1Ωk(ω)V(C(τk,ω),u(τk,ω),p(τk,ω),b(τk,ω),A(τk,ω)))⩾εmin{k−1−lnk,1k−1+lnk}, |
where 1Ωk is the indicator function of Ωk. Letting k→∞ leads to
∞>V(C(0),u(0),p(0),b(0),A(0))+TK=∞. |
This is a contradiction. As a consequence, τ∞=∞ a.s. The proof is completed.
Theorem 2. For any initial value X(0)=(C(0),u(0),p(0),b(0),A(0))∈R5+, the solutions of the model (2.2) are stochastically ultimately bounded and permanent.
Proof. For facilitate calculation, define N=nA+mC+u+p+2b, choosing Λ=min{η,k1,k2−mv2,k3+mv3,k4}, 0<m<min{k2v2,k3v3} and define
V=1N+N. |
By using the Itô's formula, we have
LV=mλ1+λ2+λ3−ηnA+mv2u−mv3p−mk1C+v1Ck+C−ρuA−k2u−k3p−2k4b−1N2(mλ1+λ2+λ3−ηnA+mv2u−mv3p−mk1c+v1Ck+C−ρuA)+1N2(−k2u−k3p+2k4b)+1N3(ξ25n2A2+ξ21m2C2+ξ22u2+ξ23p2+4ξ24b2)⩽mλ1+λ2+λ3+v1−ηnA−mk1C−(k2−mv2)u−(k3+mv3)p−2k4b−1N2(mλ1+λ2+λ3+v1)−1N2(−ηnA−mk1C−(k2−mv3)u)+1N2(−(k3−mv3)p+2k4b)+1N3(ξ25n2A2+ξ21m2C2+ξ22u2+ξ23p2+4ξ24b2)⩽mλ1+λ2+λ3+v1−Λ(nA+mC+u+p+2b)−1N2(mλ1+λ2+λ3+v1)+1N2(−ηnA−mk1C−(k2−mv3)u−(k3−mv3)p−2k4b)+1N(Λ+ξ25+ξ21+ξ22+ξ23+ξ24)⩽G−ΛV, |
where
G=4(mλ1+λ2+λ3+v1)2+(Λ+ξ25+ξ21+ξ22+ξ23+ξ24)24(mλ1+λ2+λ3+v1). |
Then, by a similar proof of Theorem 4.3 in literature [32] we can get the X(t) of model (2.2) is V-geometrically ergodic. And through a simple calculation we have
E[eΛtV]=E[V(0)]+E[∫t0eΛs(ΛV(s)+LV(s))ds]⩽E[V(0)]+GE[∫t0eΛsds]=E[V(0)]+GΛ(eΛt−1). |
It follows that
E[V(t)]⩽e−ΛtE[V(0)]+GΛ(1−e−Λt)⩽E[V(0)]+GΛ:=H. |
Thus, limt→∞supE[V(t)]⩽H, we chose a constant χ which is sufficiently large, such that Hχ<1. By using Chebychev inequality in Lemma {1},
P{V(t)>χ}⩽1χE[V(t)]⩽Hχ:=ε. |
Note that,
1−ε⩽P{V(t)⩽χ}⩽P{1χ⩽N⩽χ}. |
That means,
P{N>χ}+P{N<1χ}<ε. |
Thus,
P{∣A(t),C(t),u(t),p(t),b(t)∣>χ}⩽P{N>χ}<ε. |
According to Definition 3 and Definition 6, model (2.2) is stochastically ultimately bounded and permanent. The proof is completed.
In this section, we will consider whether there is a unique stationary distribution of the model (2.2) that allows the disease to persist rather than die off.
Theorem 3. If there exist constants ci(i=1,2,3) such that inequality (4.1) holds then for any initial value
X(0)=(C(0),u(0),p(0),b(0),A(0))∈R5+, |
the model (2.2) admits a unique stationary distribution μ(⋅) and it has the ergodic feature.
{c1ηn−ρ>0,c2k2−v2−τ>0,c3k3−τ>0,c2−c1>0. | (4.1) |
Proof. According to Lemma 5, the diffusion matrix of model (2.2) is given by
a(x)=[ξ21C200000ξ22u200000ξ23p200000ξ24b200000ξ25A2]. |
Choose
G=min(C,u,p,b,A)∈Dδ⊂R4+{ξ21C2,ξ22u2,ξ23p2,ξ24b2,ξ21A2}, |
we can get that
4∑i,j=1aij(C,u,p,b,A)θiθj=ξ21C2θ22+ξ22u2θ22+ξ23p2θ23+ξ24b2θ24+ξ25A2θ25⩾G‖θ‖2, |
for any (C,u,p,b,A)∈D,θ=(θ1,θ2,θ3,θ4,θ5)∈R5+. Then the condition (1) in Lemma 2 is satisfied.
To prove condition (2) of Lemma 2 is fulfilled, we need to develop a non-negative C5−function V: R5+→R. To do this, we first define
V1(C,u,p,b,A)=c1nA+C+c2u+c3p+(c2+c3)b. |
By using the Itô's formula in the proposed model (2.2), we obtain
L(−lnC)=−λ1C−v2uC−v3PC+k1+ξ212,L(−lnu)=−λ2u+k2+τp−σbu−v1C(k+C)u+αnun−1+ρA+ξ222,L(−lnp)=−λ3p+k3+τu−σbp+ξ232,L(−lnb)=−τupb+σ+δ+ξ242,L(−lnnA)=−αunA+η+n2ξ252. |
Therefore, we have
LV1=L(c1nA+C+c2u+c3p+(c2+c3)b)=c1αnun−c1ηnA+λ1+v2u−v3pC−k1C+c2λ2+c2v1Ck+C−c2αnun−c2ρuA−c2k2u−c3k3p−(c2+c3)k4b⩽−(c2−c1)αnun−c1ηnA−k1C−(c2k2−v2)u−c3k3p−(c2+c3)k4b+λ1+c2λ2+c2v1. |
Let
V2(C,u,p,b,A)=V1−lnnA−lnC−lnu−lnp−lnb. |
In addition, we can obtain
LV2=LV1−αunA+η+n2ξ252−λ1C−v2uC−v3PC+k1+ξ212−λ2u+k2+τp−σbu−v1C(k+C)u+αnun−1+ρA+ξ222−λ3p+k3+τu−σbp+ξ232−τupb+σ+δ+ξ242⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb−(c2−c1)αnun+αnun−1+λ1+c2λ2+c2v1+η+k1+k2+k3+σ+δ+n2ξ252+ξ212+ξ222+ξ232+ξ242. |
For the sake of simplicity, we define
F=max{−(c2−c1)αnun+αnun−1+λ1+c2λ2+c2v1+η+k1+k2+k3+σ+δ+n2ξ252+ξ212+ξ222+ξ232+ξ242}. |
Also,
M=max{F,v2+v3,σ}. |
Now we define a C5-function V(C,u,p,b,A)∈R5+ as follows
V(C,u,p,b,A)=V2(C,u,p,b,A)−V2(C0,u0,p0,b0,A0). |
Applying the Itô's formula and using the proposed model, we get
LV⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M. |
The next step is to define the set
D={ε⩽C⩽1ε,ε⩽u⩽1ε,ε⩽p⩽1ε,ε3⩽b⩽1ε3,εn+1⩽A⩽1εn+1}, |
where 0<ϵ<1 is a constant that is sufficiently small and satisfies the following Eq (4.2)
ε=12min{αM,λ1M−c2−c3,λ2M−σ,τM,c1ηn−pM,k1M,c2k2−v2−τM,c2k3−τM,(c2+c3)k4M}. | (4.2) |
We divide the domain R5+∖D into the ten regions is follows
D1={(C,u,p,b,A)∈R5+,0<C<ε},D6={(C,u,p,b,A)∈R5+,C>1ε},D2={(C,u,p,b,A)∈R5+,0<u<ε},D7={(C,u,p,b,A)∈R5+,u>1ε},D3={(C,u,p,b,A)∈R5+,0<p<ε},D8={(C,u,p,b,A)∈R5+,p>1ε},D4={(C,u,p,b,A)∈R5+,0<b<ε3},D9={(C,u,p,b,A)∈R5+,b>1ε3},D5={(C,u,p,b,A)∈R5+,0<A<εn+1},D10={(C,u,p,b,A)∈R5+,A>1εn+1}. |
Obviously, Θcε=R5+/Θc=D10i=1Θi. In what follows, we will prove that
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈R5+. |
We divide the proof into ten cases.
Case 1: If (C,u,p,b,A)∈D1, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(λ1+v2ε+v3ε)+M⩽−λ1ε+M−v2−v3. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D1. |
Case 2: If (C,u,p,b,A)∈D2, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(λ2+σε)+M⩽−λ2ε+M−σ. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D2. |
Case 3: If (C,u,p,b,A)∈D3, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(λ3+σε)+M⩽−λ3ε+M−σ. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D3. |
Case 4: If (C,u,p,b,A)∈D4, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−τε2ε3+M⩽−τε+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D4. |
Case 5: If (C,u,p,b,A)∈D5, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−αεnεn+1+M⩽−αε+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D5. |
Case 6: If (C,u,p,b,A)∈D6, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−k1ε+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D6. |
Case 7: If (C,u,p,b,A)∈D7, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(c2k2−v2−τ)+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D7. |
Case 8: If (C,u,p,b,A)∈D8, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(c3k3−τ)+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D8. |
Case 9: If (C,u,p,b,A)∈D9, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−1ε(c2+c3)k4+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D9. |
Case 10: If (C,u,p,b,A)∈D10, we can derive that
LW⩽−(c1ηn−ρ)A−k1C−(c2k2−v2−τ)u−(c3k3−τ)p−(c2+c3)k4b−αunA−1C(λ1+v2u+v3P)−1u(λ2+σb)−1p(λ3+σb)−τupb+M⩽−c1ηn−ρε+M. |
According to (4.2),
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈D10. |
Including the analysis from Cases 1 to 10, we can derive that
LW(C,u,p,b,A)<0, for any (C,u,p,b,A)∈R5+. |
Consequently, condition (2) in Lemma 2 is satisfied. This finishes the proof.
In this section we are going to discuss under what conditions the disease will be extinct, for convenient, we define ⟨X(t)⟩=1t∫t0x(r)dr, and define another threshold parameter as follows:
R1=(σ+k4)(λ2+v1)k4(σ+k4+ξ242),R2=λ2+v1η+ξ252. |
Theorem 4. If R1<1 and R2<1 hold, the b(t) and A(t) will die out with probability one, moreover
limt→∞A(t)=0,limt→∞p(t)=λ3k3,limt→∞b(t)=0,a.s. |
Proof. By using the Itô's formula to the equation of model (2.2), we can get
d(σσ+k4b+u)=[λ2−k4σ+k4τup+v1ck+c−αnun−ρμA−k2μ]dt+ξ2udB2(t)+σσ+k4ξ4bdB4(t). |
Integration both sides of the equation above from 0 to t, we get
σσ+k4b(t)−b(0)t+u(t)−u(0)t=λ2−k4σ+k4⟨τup⟩+v1⟨ck+c⟩−⟨αnun⟩−ρ⟨uA⟩−k2⟨u⟩+ξ2t∫t0u(s)dB2(s)+σξ4(σ+k4)t∫t0b(s)dB4(s). |
By simple calculation, we can obtain
⟨τup⟩=σ+k4k4(λ2+v1⟨ck+c⟩)−σ+k4k4(⟨αnun⟩+ρ⟨uA⟩+k2⟨u⟩)+ϕ1(t), |
where the value of ϕ1(t) is defined via the subsequent equation
ϕ1(t)=σ1k4k4⋅ξ2tM1(t)+σξ4k4tM2(t)−σk4b(t)−b(0)t−σ+k4k4u(t)−u(0)t. |
With the large number theorem as stated in Lemma 3 and local martingales, limt→∞ϕ1(t)=0. Similarly, we also can get
⟨αnun⟩=λ2+v1⟨ck+c⟩−(k4σ+k4⟨τup⟩+ρ⟨uA⟩+k2⟨u⟩)+ϕ2(t), |
where ϕ2(t) is defined by
ϕ2(t)=ξ2tM1(t)+σξ4(σ+k4)tM2(t)−σσ+k4b(t)−b(0)t−u(t)−u(0)t. |
Similarly, limt→∞ϕ2(t)=0.
Likewise, we integrate both sides of the last two equations of the proposed model (2.2), yielding these equations
d(p+b)=λ3−k3p−k4b+ξ3pdB3(t)+ξ3bdB4(t) |
and
p(t)−p(0)t+b(t)−b(0)t=λ3−k3⟨p⟩−k4⟨b⟩+ξ3t∫t0p(s)dB3(t)+ξ4t∫t0b(s)dB4(t). |
With a simple calculation, we can get
⟨p⟩=λ3k3−k4k3⟨b⟩+ϕ3(t), |
where
ϕ3(t)=1k3[−p(t)−p(0)t−b(t)−b(0)t+ξ3t∫t0p(s)dB3(s)+ξ4t∫t0b(s)dB4(s)]. |
Clearly, limt→∞ϕ3(t)=0.
By using the Itô's formula on the fourth equation of model (2.2), we have
dlnb(t)=⟨τupb⟩−(σ+k4)−ξ242+ξ4t∫t0B4(t)⩽σ+k4k4(λ2+v1⟨ck+c⟩)−σ+k4k4(⟨αnun⟩+ρ⟨uA⟩+k2⟨u⟩)+ϕ1(t)−(σ+k4)−ξ242+ξ4t∫t0B4(t)⩽(σ+k4)(λ2+v1)k4+ϕ1(t)−(σ+k4+ξ242)+ξ4t∫t0B4(t)=(σ+k4+ξ242)(R1−1)+ϕ1(t)+ξ4t∫t0B4(t). |
Obviously,
limt→∞supξ4t∫t0B4(t)=0,a.s. |
Therefore when R1<1, we obtain
limt→∞suplnb(t)t⩽(σ+k4+ξ242)(R1−1)<0. |
That implies that,
limt→∞b(t)=0,a.s. |
In the same way, by applying the Itô's formula to the last equation of model (2.2), we can obtain,
dlnnA=⟨αnunnA⟩−η−ξ252+ξ5t∫t0B5(t)⩽⟨αnun⟩−η−ξ252+ξ5t∫t0B5(t)=λ2+v1⟨ck+c⟩−(k4σ+k4⟨τup⟩+ρ⟨uA⟩+k2⟨u⟩)+ϕ2(t)−η−ξ252+ξ5t∫t0B5(t)⩽λ2+v1−(η+ξ252)+ϕ2(t)+ξ5t∫t0B5(t)=(η+ξ252)(R2−1)+ϕ2(t)+ξ5t∫t0B5(t). |
Obviously,
limt→∞supξ5t∫t0B5(t)=0,a.s. |
Therefore when R2<1, we obtain
limt→∞suplnnA(t)t⩽(η+ξ252)(R2−1)<0. |
It implies that,
limt→∞nA(t)=0,a.s. |
That is to say
limt→∞A(t)=0,a.s. |
With ⟨p⟩=λ3k3−k4k3⟨b⟩+ϕ3(t) above, we can get that
limt→∞p(t)=λ3k3,a.s. |
This completes the proof.
Remark 1. Theorem 4 reveals that the extinction or not of the disease depends on the sign of R1 and R2. With Ri<1(i=1,2), both the Aβ oligomers and Aβ-x-PrPC complex incline to go extinct. That is, stochastic perturbations of the environment are beneficial to the extinction of both materials. This means that in real life, it is useful to pay attention to the physical condition of the patient and improve the internal environment of the body [33]. A more interesting result is that such random perturbations may lead to disease extinction. This provides a theoretical basis for disease cure.
To illustrate the theoretical results obtained, we give some examples in this section. Using the Milstein's higher order method developed in [34], we present our results. Let us consider the corresponding discretizing equations,
{Ci+1=Ci+(λ1+v2ui−v3piCi−k1Ci)Δt+ξ1ϖ1,iCi√Δt+12ξ21Ci(ϖ21,i−1)Δt,ui+1=ui+(λ2−τuipi+σbi+v1Cik+Ci−αnuni−ρuiAi−k2ui)Δt+ξ2ϖ2,iui√Δt+12ξ22ui(ϖ22,i−1)Δt,pi+1=pi+(λ3−τuipi+σbi−k3pi)Δt+ξ3ϖ3,ipi√Δt+12ξ23pi(ϖ23,i−1)Δt,bi+1=bi+(τuipi−σbi−k4bi)Δt+ξ4ϖ4,ibi√Δt+12ξ24bi(ϖ24,i−1)Δt,Ai+1=Ai+(αuni−ηAi)Δt+ξ5ϖ5,iAi√Δt+12ξ25Ai(ϖ25,i−1)Δt. |
Where ϖj,ij=1,2,3,4,5 are the realization of five independent Gaussian random variables with distribution N(0,1) and time step Δt=0.01. Using MATLAB, numerical simulations were performed on the proposed stochastic Alzheimer's disease model (2.2) and an approximate solution of the model is obtained. In addition, it is shown that noise intensity has a significant influence. By assuming numerical values of the parameters related to their biological feasibility, we verified the extinction of the disease and the existence of a stationary distribution.
First, we choose λ1=0.2, v1=1, v2=0.6, v3=0.4, k1=7, ξ1=0.1, k=0.3, k2=0.35, ρ=0.5, ξ2=0.25, λ3=0.5, k3=0.2, ξ3=0.2, τ=0.85, σ=0.6, η=0.8, α=0.3, n=3, ξ5=0.5, ξ4=0.1. Furthermore, we consider the initial size of population density as X(0)=(C(0),u(0),p(0),b(0),A(0))=(0.2,0.5,0.5,1.2,1). These assumptions satisfy the Theorem 3, which implies that model (2.2) has a unique stationary distribution as shown in Figure 1 and means the disease will be persistent.
Next, based on the previous assumptions, we change λ1, v1, ξ1, k2, ξ2, λ3, ξ3, η, ξ4, ξ5 to be λ1=0.02, v1=0.08, ξ1=2.8, k2=3, ξ2=4, λ3=0.85, ξ3=5, η=0.12, ξ4=0.6 and ξ5=1.6. We can easily calculate the basic reproduction number R1=0.8556<1 and R2=0.2357<1. And according to Theorem 4 the solution of model (2.2) must obey
limt→∞suplnb(t)t⩽(σ+k4+ξ242)(R1−1)<0 |
and
limt→∞suplnnA(t)t⩽(η+ξ252)(R2−1)<0. |
This means that the disease will die out in this case and the numerical simulation of Figure 2 confirms our theoretical results. Figure 2 shows that the stochastic equation (2.2) and the deterministic equation have differences in their behavior. By this, we can point out that the disease tends towards the extinction with environmental noise. The numerical simulation shows that the surrounding noise have a very large effect on the mentioned disease. That is, the environmental interference will cause the Aβ plaque and Aβ−x−PrPC complex to disappear.
Finally, to simulate the effect of different intensities of environmental interference, we fix the parameters above except ξ4 and ξ5. We change the values of ξ4 and ξ5 in Figure 3. As the intensity of white noise increases, Aβ plaques and Aβ-x-PrPC complex will accelerate extinction.
During neural signaling, the concentration of Aβ is influenced by a number of stochastic factors. For example, calcium ions can regulate of Aβ levels in the interstitial fluid (ISF) by affecting the permeability of the cell membrane. We established a random Alzheimer's disease model containing Ca2+ and investigated the transmission dynamics with changing biological environment. Using the stochastic Lyapunov functions theory, the existence and positivity were proved. The extinction and the stationary distribution were also discussed, the related conditions implied that the random parameters such as the random of Ca2+ concentration will lead to disease's extinction. In contrast to the optimal control conditions proposed by Hu et al. [14], this paper directly derives more explicit and simple conditions for the extinction of Aβ plaques and Aβ−x−PrPC complex, which will form the basis in formulating novel therapeutic solutions for control strategies regarding AD pathology. In the future, the model can be further extended by adding drugs. One can also talk about the drug-target kinetics of the model by adding drugs and the influence of toxicological effects of drugs on therapeutic efficacy.
The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.
This work was supported by the National Natural Science Foundation of China (Nos. 12271068, 11961024), the Group Building Scientific Innovation Project for Universities in Chongqing (No. CXQT21021), the Joint Training Base Construction Project for Graduate Students in Chongqing (No. JDLH PYJD2021016), the Innovation Project for Graduate Research in Chongqing Jiaotong University (No. 2023ST011).
The authors declare that they have no conflicts of interest related to this article.
[1] |
S. Jean-Marie, Z. Jadwiga, J. Pierre, A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease, J. Alzheimer's Dis., 30 (2012), 17–26. https://doi.org/10.3233/JAD-2012-111964 doi: 10.3233/JAD-2012-111964
![]() |
[2] |
R. Bai, W. Dong, Trends in mortality rates for Alzheimer's disease and other dementias over 30 years in China, Am. J. Alzheimer's Dis., 36 (2021), 1–8. https://doi.org/10.1177/15333175211044884 doi: 10.1177/15333175211044884
![]() |
[3] |
Alzheimer's Association Report, 2021 Alzheimer's disease facts and figures, Alzheimer's Dement., 17 (2021), 327–406. https://doi.org/10.1002/alz.12328 doi: 10.1002/alz.12328
![]() |
[4] |
L. Söderberg, M. Johannesson, P. Nygren, H. Laudon, F. Eriksson, G. Osswald, et al., Lecanemab, Aducanumab, and Gantenerumab–Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease, Neurotherapeutics, 20 (2023), 195–206. https://doi.org/10.1007/s13311-022-01308-6 doi: 10.1007/s13311-022-01308-6
![]() |
[5] |
J. Cummings, P. Aisen, C. Lemere, A. Atri, M. Sabbagh, S. Salloway, Aducanumab produced a clinically meaningful benefit in association with amyloid lowering, Alz. Res. Therapy, 13 (2021), 98. https://doi.org/10.1186/s13195-021-00838-z doi: 10.1186/s13195-021-00838-z
![]() |
[6] |
K. Wojtunik-Kulesza, M. Rudkowska, A. Orzeł-Sajdłowska, Aducanumab-Hope or disappointment for Alzheimer's disease, Int. J. Mol. Sci., 24 (2023), 4367. https://doi.org/10.3390/ijms24054367 doi: 10.3390/ijms24054367
![]() |
[7] |
Y. Huang, L. Mucke, Alzheimer mechanisms and therapeutic strategies, Cell, 148 (2012), 1204–1222. https://doi.org/10.1016/j.cell.2012.02.040 doi: 10.1016/j.cell.2012.02.040
![]() |
[8] |
M. P. Lambert, A. K. Barlow, B. A. Chromy, W. L. Klein, Diffusible, nonfibrillar ligands derived from Aβ1−42 are potent central nervous system neurotoxins, Proc. Natl. Acad. Sci. USA, 95 (1998), 6448–6453. https://doi.org/10.1073/pnas.95.11.6448 doi: 10.1073/pnas.95.11.6448
![]() |
[9] |
M. Hoore, S. Khailaie, G. Montaseri, T. Mitra, M. Meyer-Hermann, Mathematical model shows how sleep may affect amyloid-β fibrillization, Biophys. J., 119 (2018), 862–872. https://doi.org/10.1016/j.bpj.2020.07.011 doi: 10.1016/j.bpj.2020.07.011
![]() |
[10] |
H. Li, H. Zhao, Mathematical model of Alzheimer's disease with prion proteins interactions and treatment, Appl. Math. Comput., 433 (2022), 127377. https://doi.org/10.1016/j.amc.2022.127377 doi: 10.1016/j.amc.2022.127377
![]() |
[11] |
F. Dohler, D. Sepulveda-Falla, S. Krasemann, H. Altmeppen, H. Schlüter, D. Hildebrand, et al., High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease, Brain, 137 (2014), 873–886. https://doi.org/10.1093/brain/awt375 doi: 10.1093/brain/awt375
![]() |
[12] |
B. Mroczko, M. Groblewska, A. Litman-Zawadzka, J. Kornhuber, P. Lewczuk, Amyloid β oligomers (AβOs) in Alzheimer's disease, J. Neural Transm., 125 (2018), 177–191. https://doi.org/10.1007/s00702-017-1820-x doi: 10.1007/s00702-017-1820-x
![]() |
[13] |
M. Helal, E. Hingant, L. Pujo-Menjouet, G. F. Webb, Alzheimer's disease: analysis of a mathematical model incorporating the role of prions, J. Math. Biol., 69 (2014), 1207–1235. https://doi.org/10.1007/s00285-013-0732-0 doi: 10.1007/s00285-013-0732-0
![]() |
[14] |
J. Hu, Q. Zhang, A. Meyer-Baese, M. Ye, Finite-time stability and optimal control of a stochastic reaction-diffusion model for Alzheimer's disease with impulse and time-varying delay, Appl. Math. Model., 102 (2022), 511–539. https://doi.org/10.1016/j.apm.2021.10.004 doi: 10.1016/j.apm.2021.10.004
![]() |
[15] |
B. Fang, D. Wang, M. Huang, G. Yu, H. Li, Hypothesis on the relationship between the change in intracellular pH and incidence of sporadic Alzheimer's disease or vascular dementia, Int. J. Neurosci. 120 (2010), 591–595. https://doi.org/10.3109/00207454.2010.505353 doi: 10.3109/00207454.2010.505353
![]() |
[16] |
A. De Mario, C. Peggion, M. L. Massimino, F. Viviani, A. Castellani, M. Giacomello, et al., The prion protein regulates glutamate-mediated Ca2+ entry and mitochondrial Ca2+ accumulation in neurons, J. Cell Sci., 130 (2017), 2736–2746. https://doi.org/10.1242/jcs.196972 doi: 10.1242/jcs.196972
![]() |
[17] |
H. J. Kwon, M. Y. Cha, D. Kim, D. K. Kim, M. Soh, K. Shin, et al., Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer's disease, ACS Nano, 10 (2016), 2860–2870. https://doi.org/10.1021/acsnano.5b08045 doi: 10.1021/acsnano.5b08045
![]() |
[18] |
A. Pannaccione, I. Piccialli, A. Secondo, R. Ciccone, P. Molinaro, F. Boscia, et al., The Na+/Ca2+exchanger in Alzheimer's disease, Cell Calcium, 87 (2020), 102190. https://doi.org/10.1016/j.ceca.2020.102190 doi: 10.1016/j.ceca.2020.102190
![]() |
[19] |
J. De Caluwé, G. Dupont, The progression towards Alzheimer's disease described as a bistable switch arising from the positive loop between amyloids and Ca2+, J. Theor. Biol., 331 (2013), 12–18. https://doi.org/10.1016/j.jtbi.2013.04.015 doi: 10.1016/j.jtbi.2013.04.015
![]() |
[20] | B. Øksendal, Stochastic differential equations: an introduction with applications, Heidelberg: Springer Berlin, 2003. https://doi.org/10.1007/978-3-642-14394-6 |
[21] |
M. Xin, B. Wang, Stationary distribution and extinction of a stochastic tuberculosis model, Phys. A, 545 (2020), 123741. https://doi.org/10.1016/j.physa.2019.123741 doi: 10.1016/j.physa.2019.123741
![]() |
[22] |
M. Liu, M. Deng, Permanence and extinction of a stochastic hybrid model for tumor growth, Appl. Math. Lett., 94 (2019), 66–72. https://doi.org/10.1016/j.aml.2019.02.016 doi: 10.1016/j.aml.2019.02.016
![]() |
[23] |
Y. Tan, Y. Cai, X. Wang, Z. Peng, K. Wang, R. Yao, et al., Stochastic dynamics of an SIS epidemiological model with media coverage, Math. Comput. Simul., 204 (2023), 1–27. https://doi.org/10.1016/j.matcom.2022.08.001 doi: 10.1016/j.matcom.2022.08.001
![]() |
[24] |
J. Hu, Q. Zhang, A. Meyer-Baese, M. Ye, Stationary distribution of a stochastic Alzheimer's disease model, Math. Methods Appl. Sci., 43 (2020), 9706–9718. https://doi.org/10.1002/mma.6642 doi: 10.1002/mma.6642
![]() |
[25] |
T. Matsubara, K. Satoh, T. Homma, T. Nakagaki, N. Yamaguchi, R. Atarashi, et al., Prion protein interacts with the metabotropic glutamate receptor 1 and regulates the organization of Ca2+ signaling, Biochem. Biophys. Res. Commun., 525 (2020), 447–454. https://doi.org/10.1016/j.bbrc.2020.02.102 doi: 10.1016/j.bbrc.2020.02.102
![]() |
[26] |
J. Latulippe, D. Lotito, D. Murby, A mathematical model for the effects of amyloid beta on intracellular calcium, PLoS One, 13 (2018), 1–27. https://doi.org/10.1371/journal.pone.0202503 doi: 10.1371/journal.pone.0202503
![]() |
[27] |
A. Din, T. Khan, Y. Li, H. Tahir, A. Khan, W. A. Khan, Mathematical analysis of dengue stochastic epidemic model, Results Phys., 20 (2021), 103719. https://doi.org/10.1016/j.rinp.2020.103719 doi: 10.1016/j.rinp.2020.103719
![]() |
[28] |
W. Wang, A. Zazoua, Analysis of mathematical model of prostate cancer with androgen deprivation therapy, Commun. Nonlinear Sci. Numer. Simul., 66 (2019), 41–60. https://doi.org/10.1016/j.cnsns.2018.06.004 doi: 10.1016/j.cnsns.2018.06.004
![]() |
[29] |
Y. Wang, D. Jiang, Stationary distribution and extinction of a stochastic viral infection model, Discrete Dyn. Nat. Soc., 2017 (2017), 6027509. https://doi.org/10.1155/2017/6027509 doi: 10.1155/2017/6027509
![]() |
[30] | R. Khasminskii, Stochastic stability of differential equations, Heidelberg: Springer Berlin, 2012. https://doi.org/10.1007/978-3-642-23280-0 |
[31] |
X. Mao, C. Yuan, J. Zou, Stochastic differential delay equations of population dynamics, J. Math. Anal. Appl., 304 (2005), 296–320. https://doi.org/10.1016/j.jmaa.2004.09.027 doi: 10.1016/j.jmaa.2004.09.027
![]() |
[32] |
G. Lan, Z. Lin, C. Wei, S. Zhang, A stochastic SIRS epidemic model with non-monotone incidence rate under regime-switching, J. Franklin Inst., 16 (2019), 9844–9866. https://doi.org/10.1016/j.jfranklin.2019.09.009 doi: 10.1016/j.jfranklin.2019.09.009
![]() |
[33] |
J. Olazarán, B. Reisberg, L. Clare, I. Cruz, J. Peña-Casanova, T. del Ser, et al., Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy, Dement. Geriatr. Cogn. Disord., 30 (2010), 161–178. https://doi.org/10.1159/000316119 doi: 10.1159/000316119
![]() |
[34] |
D. J. Higham, An algorithmic introduction to numerical simulation of stochastic differential equations, SIAM Rev., 43 (2001), 525–546. https://doi.org/10.1137/S0036144500378302 doi: 10.1137/S0036144500378302
![]() |
1. | Mitali Maji, Subhas Khajanchi, Mathematical models on Alzheimer's Disease and its treatment: A review, 2025, 15710645, 10.1016/j.plrev.2025.01.004 |